Other strategies involve the use of tumor-associated promoters to drive the expression of E1A, like CG0070 (E2F1 promoter)50, OBP-301 (hTERT promoter)51, CRAd-S-pk7 (Survivin promoter)52, and AdVince (CgA promoter)53, that can be combined with d24 mutation to further improve selectivity, like in SynOV1.154, VCN-0155, TILT-12356, or LOAd-70357. Here, BIRC5 is linked to neoplasm.